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ABSTRACT The structure of the metalloproteinase and
hemorrhagic toxin atrolysin C form d (EC 3.4.24.42), from the
venom of the western diamondback rattlesnake Crotalus atrox,
has been determined to atomic resolution by x-ray crystallo-
graphic methods. This study illuminates the nature of inhibitor
binding with natural (<Glu-Asn-Trp, where <Glu is pyroglu-
tamic acid) and synthetic (SCH 47890) ligands. The primary
specificity pocket is exceptionally deep; the nature of inhibitor
and productive substrate binding is discussed. Insights gained
from the study of these complexes facilitate the design of
potential drugs to treat di where matrix metalloprotein-
ases have been implicated, e.g., arthritis and tumor metastasis.
Hemorrhagic metalloproteinases (MPs) from the western
diamondback rattlesnake Crotalus atrox are members of the
reprolysin subfamily of zinc MPs (1), which includes venom
MPs and the mammalian reproductive proteins, e.g., PH30
isolated from guinea pig sperm (2). Venom proteinases can be
divided into four classes (P-I to P-IV) that minimally share
homologous (P-I) proteinase domains; classes P-II to P-IV
have additional domains located C-terminal to the proteinase
domain (3). Atrolysin C (EC 3.4.24.42) is the trivial name
given to C. atrox hemorrhagic isoenzymes [forms c and d
(Ht-c and d, respectively) class P-I, 202 amino acids, 1 Zn,
and 1 Ca] that differ by only 1 amino acid (Ala-180 -* Asp;
refs. 3 and 4). Ht-d efficiently cleaves basement membrane
proteins surrounding capillaries, permitting the flux of cap-
illary contents into the surrounding stroma, producing hem-
orrhage (5), and toxins into the circulatory system. Enzy-
matic activity, hence hemorrhage, can be inhibited by re-
moval of the zinc atom, by synthetic inhibitors (6), by
endogenous venom peptides [<Glu-Asn-Trp (where <Glu is
pyroglutamic acid) = pENW], or by human a2-macroglobulin
(7, 8).
The reprolysins share some structural similarities with the
other zinc MP subfamilies, including the matrix MPs
(MMPs), the astacins, and the serralysins (large bacterial
proteinases), primarily in the region of the zinc binding site
(9). Both the reprolysins and the MMPs appear to maintain
enzyme latency by the mechanism of a "cysteine switch," a
short consensus sequence found in the pro-domains of these
proteinases with a common Cys-Gly-Val locus, that interacts
with active-site zinc effectively preventing substrate binding
(1, 10). Functionally, both the reprolysins and the MMP
members seem to be primarily involved in the hydrolysis of
extracellular matrix (1, 11), based on common structural
features.
The crystal structure of a class P-I native venom MP,
adamalysin II, from Crotalus adamanteus (EC 3.4.24.46;
80% sequence similarity to Ht-d) has been described (12), as
was the native digestive MP, astacin (13). A high degree of
tertiary structure conservation among the astacin, reprol-
ysin, serralysins, and theMMP subfamilies is observed (9, 14)
at the active site, suggesting that the structural principles that
govern the interaction of substrates and inhibitors with
members of these subfamilies are likely to be similar if not
identical. Substrates and synthetic inhibitors of the MMPs
have been discussed (15) and potent MMP inhibitors have
been reported: e.g., SC 44463 (16), GM 6001 (17), or BB-94
(18). We here report the crystal structure of Ht-d in its native
and inhibited forms, bound to compounds 1 (pENW) and 2
[SCH 47890 (SCH)].** The Ki value of 1 with Ht-d is 3.5 juM
(1 is present in venom at millimolar concentrations; ref. 7);
the Ki value of 2 with Ht-d is 0.52 juM and with human type
IV collagenase (MMP-2) is 0.23 juM (19).
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<Glu oligopeptides inhibit certain MPs physiologically,
e.g., <Lys-Trp-Ala-Pro (where <Lys is pyrolysine) inhibits
angiotensinogen-converting enzyme (20), contributing to the
design of active drugs, e.g., captopril, to control hyperten-
sion (21). Typically, small oligopeptides bind poorly (milli-
molar Ki values) to this class of proteolytic enzymes; thus,
because of their potency, compounds 1 and 2 are candidates
for the study of inhibitor binding, leading to an enhanced
understanding of inhibitor (and hence substrate) binding and
providing valuable insight into substrate interaction and
inhibitor design.
MATERIALS AND METHODS
Ht-d was purified by column chromatography (22) and con-
centrated to 10 mg/ml in 0.1 M imidazole buffer (pH 6.8). By
using the vapor diffusion method, crystals grew with 20 mM
CaCl2 and 2.4 M (NH4)2SO4 as thick needles (0.4 x 0.4 x 3
mm) with space group P65 (extinctions, cross phasing, and
Abbreviations: Ht-d, atrolysin C form d; MP, metalloproteinase;
MMP, matrix MP; NATI, native Ht-d; pENW, <Glu-Asn-Trp,
where <Glu is pyroglutamic acid; SCH, SCH 47890.
*Present address: Institut de Biologica Fonamental, Universitat
Autonoma de Barcelona, 08193 Bellaterra, Barcelona, Spain.
IlTo whom reprint requests should be addressed.
**The atomic coordinates have been deposited in the Protein Data
Bank, Chemistry Department, Brookhaven National Laboratory,
Upton, NY 11973 (reference 1HTD).
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Table 1. Crystallographic parameters
Category NATI + pENW + SCH
Area detector Siemens Siemens Rigaku
Total reflections, no. 73,009 89,804 172,957
Unique reflections, no. 18,499 26,105 32,104
Rmerge, % 8.31 4.79 5.34
Resolution range for
refinement, A 8.0-2.2 8.0-2.05 8.0-1.85
Data completeness, % 68.3 90.0 77.9
Resolution shell, A 2.37-2.25 2.13-2.06 1.89-1.84
Data completeness, % 42.7 55.5 45.1
Number of atoms in
refinement 4187 4261 4355
R factor 19.0 17.1 17.4
rmsd bonds, A 0.016 0.013 0.012
rmsd angles, deg. 2.50 2.54 2.51
rmsd, rms deviation. Rnwrge = [MhkI ,reflhI (hklJ) - I (hkt)I/1hkl
Yreflhl (hklj)I] x 100%. R factor = (IIFobsI - lFcalcII/7 IFobsl) x
100o.
visual inspection; ref. 23), Z = 2; a = b = 97.32 A, c = 87.76
A. A native diffraction data set was measured with Cu Ka
radiation (Table 1). The molecular boundary of the two
molecules in the asymmetric unit (moll = residues 1-202 and
mol2 = residues 501-702) was observed with the aid of the
core tracing algorithm (23).
Structure Determination. Atomic coordinates of adamal-
ysin II (12) were rotated and translated (program PRONTO) to
align with discernable regions of the multiple isomorphous
replacement map (phased on U, Eu, and Au derivatives),
specifically, the Zn binding region (residues 132-152) and an
additional helical region (residues 26-44). The "empty"
model (moll, mol2, 2 Zn;R = 46%) was subjected to 50 cycles
of rigid-body X-PLOR (24) refinement with the university's
Cray Y-MP, followed by simulated annealing to remove
possible bias in the model (Table 1). The crystallographic
dimer was then submitted to all-atom refinement (8- to 2.5-A
resolution, R = 30%6) consecutively at 2.0- and 1.85-A
resolution. Side-chain positions were checked individually
(program FRODO, ref. 25) using a 10-amino acid deletion zone
to calculate AF (F. - F, difference Fourier) omit maps;
194
H-bonding environments of His, Asn, and Gln were checked,
and Ca2+ ions were added (2.30 A to OE1 of Glu-9; 2.46 and
2.50 Ato OD1 and 2 of Asp-93; 2.30 A to 0197 and 2.35 Ato
OD1 of Asn-200). [Because of this close similarity, the
following descriptions of one molecule apply to both mole-
cules in the asymmetric unit (Figs. 1 and 2).]
SCH Refinement. A native crystal was soaked for 13 h in the
physical presence of solid SCH 2 (Table 1). The empty model
was used to calculate a AF map, revealing the clear presence
of characteristic density in the active site (e.g., the methyl-Tyr
ring), indicative of inhibitor binding. Compound 2 was mod-
eled with the program MACROMODEL (27), docked into the AF
map by using the program FRODO, together with 143 discern-
able water molecules, and refined (R = 17.4%; Fig. 3).
pENW Refinement. A native crystal was soaked for 7 h in a
buffered solution of 1 (20 mg/ml) (Table 1). The empty model
was used as a starting point for the analysis of the pENW
complex. Compound 1 was modeled (27) and docked into the
AFmap. A regionally (8 A) restrained simulated annealingplus
omit map regimen (X-PLOR 3.0) was used to remove possible
bias in the active site. With 149 water molecules added, the
structure refined to R = 17.1% (Table 1 and Fig. 4).
Native Ht-d (NATI) Structure. The empty model was re-
fined and used to calculate a AFmap (Fig. 5) that surprisingly
contained a pronounced active-site density that was strik-
ingly similar to the pENW ligand in shape and location and
was duplicated in both molecules in the asymmetric unit. This
is reminiscent of a peptidic ligand located in native y-chy-
motrypsin (28). A NATI crystal was dissolved and subjected
to electron spray ionization mass spectral analysis, which
revealed six reproducible peaks in the 400- to 500-Da range,
indicative of a mixture of ligands, presumably oligopeptides.
After careful, unbiased refinement of the empty model with
pENW and SCH data, both complexes exhibited unique
residual density in the active site indicative of inhibitor
binding.
RESULTS AND DISCUSSION
Description of the Structures. Based on conserved active-
site sequences and recent structural results, Ht-d exhibits
noticeable structural similarities to MMPs (12, 14). A pre-
diction method developed by Benner et al. (29) helped
1681. I r o/ l l I f ! / fH - 17f
FIG. 1. Schematic representation of Ht-d folding.
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FiG. 2. Stereoview (RIBBON; ref. 26) of a single Ht-d molecule (residues 1-202) with His ligation (His-142, 146, and 152) of Zn at the active
site.
identify domains of secondary structure, the greatest varia-
tion occurring at domain termini. Backbone (NCaCO) atomic
positions of molecules 1 and 2 exhibit a close rms agreement
(NATI = 0.29 A; pENW = 0.15 A; SCH = 0.22 A). A diad
axis (179.750) approximately parallel to the y axis suggests
considerable pseudosymmetry, which is broken in reciprocal
space (cf. Rmerge) and real space. The virtual identity of
molecules 1 and 2 is especially broken at a few loci: residues
22-26 (0.3 A) and 193-196 (1 A), the latter including crystal
packing interactions of side chains.
Lock and Key. Because the active site of native adamalysin
II (12) is empty (except for hydration), it provides a better
reference for the analysis of possible atomic displacements
upon ligand binding. The 0.4-A rms positional difference
between adamalysin II and SCH1 demonstrates that this class
of enzyme undergoes mninimal displacement upon ligand
binding, making it a classical lock-and-key enzyme (30) and
thus an ideal target for structure-based rational drug design.
Excluding the less-well-determined termini, the greatest shift
(1.5 A) occurs at the backbone of residue 169 at the S2' site
(31); neighboring shifts are less than 1 A.
In both SCH and pENW, a common H bond (from Asn-
108) is observed and an 0 atom of the inhibitor occupies the
apical tetrahedral coordination locus of Zn, displacing a
water molecule in the native structure. Ht-d exhibits a
structural similarity to adamalysin II (12) and a human
collagenase (9, 14), which establishes the characteristic fold-
ing pattern of MMPs. Significant characteristics include the
following features: (i) The "active-site helix" (residues 132-
147), with Zn ligands (His-142 and His-146), a sharp turn
(residues 148-151), the third His ligand (His-152), and ubiq-
uitously conserved Met (Met-166), which forms the "base-
ment" of the Zn locus ("Met turn") and, (ii) thus, helps
anchor the essential strand (residues 168-172), with Pro-168
conserved in both venom and mammalian MMPs. This strand
forms one wall of the extended binding site (Figs. 2-5). (iii)
The other wall of the extended binding site is defined by the
antiparallel (3-strand (IV, residues 106-114). Substrate bind-
ing may be predicted to be dominated to a large degree by
individual residues in these two strands and the active-site-D
helix. A third parallel strand (residues 152-157, Figs. 1 and 2)
may be postulated to define a second extended binding site,
possibly to accommodate an additional collagen peptide
chain.
With predominant van der Waals contacts to both ligands,
the S1' primary specificity site containing the indole ring of
TIp (1) or the 0-methyl phenol group of derivatized Tyr (2)
is both-wider and deeper than required by typical P1' (Leu
FiG. 3. Stereoview of SCH bound to Ht-d. A double van der Waals contact surface is shown, defined by contacts with backbone
(residues 108-109 and 169-170) and side-chain (residues 108 and 170) atoms. SCH makes H bonds to an N atom in residue 108 and an 0
atom in residue 109.
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FIG. 4. Stereoview ofpENW bound to Ht-d. A double van der Waals contact surface is shown, as in Fig. 3. Si' water molecules are shown
at the lower left. pENW makes one H bond to the N at position 108.
and Ile) residues. This agrees with the reported hydrolysis by
type IV collagenase (gelatinase) of a scissile Gly-Tyr bond
(31) in type I collagen and by stromelysin ofthe Gln-Phe bond
(32), confirming the assignment of the Si' pocket and thus
providing a prime component for inhibitor design. The bot-
tom of the S1' pocket is occupied by conserved hydrophobic
residues (e.g., Val-138 and Ile-165), ca. 10 A from P1' Ca.
Sequence comparisons reveal that the amino acids defining
the extended binding site are generally hydrophobic, except-
ing the pronounced water-filled channel (Fig. 4), which links
the deep SP' pocket with the exterior of the protein, suggest-
ing a mechanism for entropic displacement of bound water
(33).
Comparisons. The hemorrhagic isozymes (a-e) of the
venom MMP from C. atrox have been shown to cleave type
IV collagen (4), one of the major structural components of
basement membranes, which both compartmentalizes tissues
(e.g., capillaries) and provides signals for cell differentiation
(34). Substrate specificity (34-38) for collagen helps charac-
terize the various MMP species and can provide insight for
the design of specific inhibitors. Type IV collagenases play
crucial roles (38) in both beneficial (cell growth and differ-
entiation, remodeling, wound healing, angiogenesis, etc.) and
pathological (periodontitis, rheumatoid arthritis, inflamma-
tion, and tumor metastasis) processes.
Interstitial and neutrophil collagenases (39) are ineffective
against type IV collagen in the basement membrane, which is
degraded by type IV collagenase (40). Collagens (e.g., types I,
1, III, and X) are characterized as tightly wound triple helices;
each chain of the triple helix in type IV collagen has 21-24
interruptions of the Gly-Xaa-Yaa repeat (41), which are gen-
erally more sensitive to proteolysis; Yaa is usually Pro or
hydroxyproline. Collagenases usually cleave a specific Gly-
Xaa bond, with Xaa a hydrophobic residue at S1' (35); this is
confirmed (32) for stromelysin (MMP-3), where model com-
pound assays probed the pronounced hydrophobic nature of
the extended binding site region (S3-S2'). Tumor-cell pene-
tration of the extracellular matrix is one of the factors in
metastasis that is linked to type IV collagenase action (16, 18).
Venom MMPs may be differentiated from mammalian
MMPs (42) on the basis of sequence similarity, inability to be
inhibited by tissue matrix MP inhibitor [ref. 4, presumably
because of the absence of the C-terminal hemopexin-like
domain (43)], and one Zn atom vs. two for the mammalian
MMPs. The second Zn and Ca atoms in mammalian MMPs
have a noncatalytic structural role (44, 45). The venom
MMPs may be most closely compared to mammalian matril-
ysin or pump (46) in terms of size and ability to cleave both
type IV collagen and gelatin. The conserved Zn-binding
(Hl42EXXHXXGXXH152) and related active-site (residues
132-149 and 168-172) domains are identified as characteristic
markers for MMPs. Recently, it has been found (14) that 75%
of all residues of the catalytic domains of venom and mam-
malian MMPs are topologically similar; 15 residues are
identical and 10 are at the Zn-binding site.
CONCLUSIONS
The following characteristics are observed:
(i) While some inhibitor design strategies have striven for
-SH binding to Zn, carboxylate (sulfonate, phosphonate,
FIG. 5. Stereo figure of the NATI AF map (all nonprotein atoms are omitted) contoured at 1.5cr, showing the size of the Si' pocket.
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etc.) ligation presents a stable, perhaps preferable alterna-
tive.
(ii) The dominant primary specificity site (Si') can contain
large aromatic or extended hydrophobic moieties, up to a
length (from Ca) of 9-10 A.
(iii) Based on sequence comparisons, the MMPs have
similar hydrophobic active site and extended binding site
characteristics.
(iv) Hydrophilic groups will generally occupy surface loci,
pointing "out" into the hydrated surface (rather than into the
hydrophobic extended binding site).
(v) The extended binding site has charged groups (e.g.,
Lys-172) at both ends.
For small molecule inhibitors, two factors dominate bind-
ing: Zn ligation and optimal (i.e., size/shape dependent) van
der Waals interactions. The anomalous micromolar binding
of a tripeptide inhibitor (e.g., pENW) deserves special at-
tention.
These analyses describe the geometric characteristics of
venom MP binding to two inhibitors, providing initial insight
into the active-site preferences of MMPs. Because venom
and mammalian enzymes possess functional and structural
similarities, the venom enzymes Ht-d and adamalysin II are
candidates for the development of physiologically useful
compounds to help control diseases associated with aberrant
regulation of collagenases. While it is now possible to create
models of putative complexes based on these structures,
experience (47) with the vagaries of binding of small molecule
ligands reinforces the necessity of experimental confirmation
of any such model, due to the ever-present possibility of
alternative binding modes of small-molecule inhibitors.
These analyses provide geometric insight into enzyme-
substrate interactions and illumination for the design of
improved inhibitors and therapeutics.
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